-
2022-501417-31-01
5
2023-08-01
melanoma
-
2024-516321-31-00
4
2023-07-07
Type 3 spinal muscular atrophy
-
2023-506872-29-00
4
2023-04-13
Alzheimer's Disease
-
2024-512590-27-00
9
2023-03-08
Non-resectable locally advanced or metastatic HER2-positive breast can
-
2024-514060-10-00
4
2023-02-02
Advanced triple-negative breast cancer (TNBC), Advanced HR[+]/HER2[–]
-
2022-500424-30-00
4
2022-12-28
Parkinson’s disease
-
2022-500652-37-00
4
2022-12-01
Advanced melanoma refractory to prior checkpoint inhibitor therapy
-
2023-505645-12-00
4
2022-11-28
Parkinson's Disease
-
2024-512737-33-00
5
2022-09-30
Facioscapulohumeral Muscular Dystrophy (FSHD)
-
2024-516064-28-00
5
2022-09-27
Acute Graft Versus Host Disease
-
2024-518403-22-00
6
2022-06-20
Diabetes mellitus II
-
2023-505457-40-00
5
2022-02-02
Previously Untreated Advanced Gastric or Gastroesophageal Junction
Can
-
2024-513123-17-00
5
2022-01-12
Non-infection uveitis
-
2023-507688-20-00
5
2021-12-03
Participants with completely resected Stage III or Stage IV melanoma
-
2023-508511-23-00
5
2021-12-02
Amyotrophic Lateral Sclerosis (ALS)
-
2024-512052-38-00
9
2021-12-02
Advanced triple negative breast cancer
-
2024-519633-35-00
6
2021-10-25
Resectable pancreatic adenocarcinoma with risk factors
-
2024-518852-22-00
3
2021-09-03
Advanced Pancreatic Cancer
-
2024-512123-37-00
5
2021-05-27
Parkinson's disease
-
2023-506919-18-00
5
2021-05-17
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
-
2023-508259-38-00
5
2021-04-29
Adult patients with relapsed or primary refractory DLBCL
-
2023-503519-13-00
4
2020-12-14
Advanced Hepatocellular Carcinoma
-
2024-511295-33-00
4
2020-08-13
Study to evaluate the effect of metformin in the prevention of hypergl
-
2023-509053-32-00
5
2019-07-17
Locoregional Hepatocellular Carcinoma (HCC)